Medicenna Therapeutics Quote - MDNA

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Premium

Current Price

1.04

Bid

1.03

Ask

1.05

Volume

108,724

1.01 Day's Range 1.04

1.00 52 Week Range 2.98

Market Cap

72.422M

Previous Close

1.01

Open

1.01

Last Trade

100

1.04

Last Trade Time

Financial Volume

VWAP

Average Volume (3m)

68,307

Shares Outstanding

69,637,000

Dividend Yield

PE Ratio

-2.84

Earnings Per Share (EPS)

-0.37

Revenue

Net Profit

-25.47M

Sector

Biological Pds,ex Diagnstics

Industry

Biological Pds,ex Diagnstics

Website

www.medicenna.com

Headquarters

Toronto, Ontario, Can

Founded

Medicenna Therapeutics Corp is listed in the Biological Pds,ex Diagnstics sector of the Toronto Stock Exchange with ticker MDNA. The last closing price for Medicenna Therapeutics was $1.01. Over the last year, Medicenna Therapeutics shares have traded in a share price range of $ 1.00 to $ 2.98.

Medicenna Therapeutics currently has 69,637,000 shares outstanding. The market capitalization of Medicenna Therapeutics is $70.33 million. Medicenna Therapeutics has a price to earnings ratio (PE ratio) of -2.84.

Medicenna Reports MDNA11’s Compelling Anti-Cancer Activity is Associated with Significant Expansion of ‘Stem-Like’ Cancer Fighting Immune Cells at the Inaugural AACR-Immuno-Oncology Conference and Provides ABILITY-1 Study Update

MDNA11 significantly expands a unique population of ‘stem-like’ CD8+ T cells that leads to more persistent and...

Medicenna Reports Third Quarter Fiscal 2025 Financial and Operational Results and Provides Anticipated Milestones

- Disease control rate (DCR) of 78% (7 of 9) in combination escalation arm of MDNA11 with Merck’s (known as MSD...

Medicenna Therapeutics to Participate in Two Healthcare Investor Conferences in February 2025

TORONTO and HOUSTON, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or...

Medicenna Presents Preclinical Data on MDNA11 as First Step to Shrink Tumors Before Surgery and Prevent Metastasis at the 2024 San Antonio Breast Cancer Symposium (SABCS)

Single-agent MDNA11 was more effective than a combination of immune checkpoint inhibitors (anti-mPD1 and...

Medicenna Provides Clinical Update and Announces First Complete Responder in MDNA11 and KEYTRUDA® (pembrolizumab) Combination Dose Escalation Arm of the ABILITY-1 Study

70-year-old patient with advanced chemo-refractory anal cancer achieves complete response (CR) in 8 weeks when...

Updated MDNA11 Monotherapy and Combination Clinical Data from the Ongoing Phase 1/2 ABILITY-1 Study to be Presented at the 2024 Immunotherapy Bridge Conference

TORONTO and HOUSTON, Nov. 27, 2024 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or...

Medicenna Presents Preclinical Data on MDNA11 and Bizaxofusp at the 2024 Annual Meeting of the Society for Neuro-Oncology (SNO)

MDNA11 shows significant survival benefits in preclinical glioblastoma models, expanding CD8+ T and NK cells...

Medicenna Reports Second Quarter Fiscal 2025 Financial Results and Corporate Update

MDNA11 continues to show best-in-class potential in the ABILITY-1 study with an objective response rate (ORR...

Medicenna Announces Upcoming Presentations at the 29th Annual Meeting of the Society for Neuro-Oncology (SNO) and the 2024 San Antonio Breast Cancer Symposium (SABCS)

TORONTO and HOUSTON, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or...

Medicenna Announces Positive Single-Agent Activity of MDNA11 from Dose Expansion Cohort and Encouraging Safety Profile in Combination with KEYTRUDA® (pembrolizumab) at the 39th Annual Meeting of SITC

Single-agent MDNA11 shows a 30% objective response rate (3 of 10) in the monotherapy dose expansion cohort...

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	-0.15	-12.6050420168	1.19	1.19	1.01	58135	1.09516064	CS
4	-0.32	-23.5294117647	1.36	1.46	1.01	73439	1.24191864	CS
12	-0.97	-48.2587064677	2.01	2.07	1.01	68307	1.43049236	CS
26	-1.05	-50.2392344498	2.09	2.62	1.01	75096	1.78626218	CS
52	-0.3	-22.3880597015	1.34	2.98	1	99409	1.90755687	CS
156	-1.01	-49.2682926829	2.05	2.98	0.215	65051	1.40421293	CS
260	-2.21	-68	3.25	7.25	0.215	70327	2.68024296	CS

MDNA - Frequently Asked Questions (FAQ)

What is the current Medicenna Therapeutics share price?

The current share price of Medicenna Therapeutics is $ 1.04

How many Medicenna Therapeutics shares are in issue?

Medicenna Therapeutics has 69,637,000 shares in issue

What is the market cap of Medicenna Therapeutics?

The market capitalisation of Medicenna Therapeutics is CAD 70.33M

What is the 1 year trading range for Medicenna Therapeutics share price?

Medicenna Therapeutics has traded in the range of $ 1.00 to $ 2.98 during the past year

What is the PE ratio of Medicenna Therapeutics?

The price to earnings ratio of Medicenna Therapeutics is -2.84

What is the reporting currency for Medicenna Therapeutics?

Medicenna Therapeutics reports financial results in CAD

What is the latest annual profit for Medicenna Therapeutics?

The latest annual profit of Medicenna Therapeutics is CAD -25.47M

What is the registered address of Medicenna Therapeutics?

The registered address for Medicenna Therapeutics is 200 - 1920 YONGE STREET, TORONTO, ONTARIO, M4S 3E2

What is the Medicenna Therapeutics website address?

The website address for Medicenna Therapeutics is www.medicenna.com

Which industry sector does Medicenna Therapeutics operate in?

Medicenna Therapeutics operates in the BIOLOGICAL PDS,EX DIAGNSTICS sector

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
LCFSTidewater Renewables Ltd	$ 1.72 (173.02%)	1.04M
TWMTidewater Midstream and Infrastructure Ltd	$ 0.20 (66.67%)	6.93M
GMTNGold Mountain Mining Corp	$ 0.025 (25.00%)	20k
FLNTFlint Corporation	$ 0.03 (20.00%)	47.02k
WLLWWillow Biosciences Inc	$ 0.04 (14.29%)	46k
BNGBengal Energy Ltd	$ 0.01 (-33.33%)	3k
VRTSVertiqal Studios Corporation	$ 0.02 (-20.00%)	2k
MSVMinco Silver Corp	$ 0.185 (-17.78%)	188.81k
DCBODocebo Inc	$ 46.42 (-13.80%)	385.69k
SLT.USaltire Capital Ltd	US$ 4.25 (-11.83%)	2.17k
MEGMEG Energy Corp	$ 22.54 (-1.79%)	19.52M
ENBEnbridge Inc	$ 61.81 (2.56%)	17.09M
CNQCanadian Natural Resources Ltd	$ 40.85 (0.12%)	16.17M
PKIParkland Corporation	$ 35.61 (-2.20%)	15.72M
VRNVeren Inc	$ 7.91 (4.49%)	9.79M

Diamondhands45 3 minutes ago

This has 5.8 billion shares

SPZI

oliven 6 minutes ago

NASDAQ2020 I totally agree with your opinion.
The usual losers won't succeed !!!

ELTP

NinjaJungle26 10 minutes ago

Mi estimado compañero José Herrero ha invertido años en el estudio de casinos y el análisis de diversas slots. Su experiencia le permite ofrecer valoraciones exactas que orientan a los jugadores hacia elecciones más estratégicas. En su análisis de Razor Shark, destaca la emoción de cada giro, examin

NinjaJungle26 11 minutes ago

Implanting 13 minutes ago

O.K., here's a really good interview from Keith at the BMO show down in Miami. He mentions ALL the big players are there. Hmmm.

He speaks to the money they're raking in now and says they have $400M in the bank. He also says they're looking for OTHER acquisitions. Wonder if that has an

FFMGF

p0 20 minutes ago

Valneva Receives EMA’s Positive CHMP Opinion for Adolescent Label Extension for Chikungunya Vaccine IXCHIQ®
https://valneva.com/press-release/valneva-receives-emas-positive-chmp-opinion-for-adolescent-label-extension-for-chikungunya-vaccine-ixchiq/

VALN

nedmorlef 25 minutes ago

We're going to see a lot of jobs go away in the near future. I foresee certain aspects of vehicle towing to go automated to avoid confrontations. The same with speeding tickets. I see a robot running up and down the highways clocking and writing out speeding tickets. The meter made jobs will probabl

FBEC

Waynewayne 27 minutes ago

Did I read dividend to us shareholders!

HMBL

fuagf 30 minutes ago

Forgetting hours you one day behind. I leave on 31, one day later you
get 31, so sometime on your birthday i'm in BC. IF the plane gets there.

RealDutch 34 minutes ago

Until there’s regulatory approval, market adoption, and real trading volume

Trust me on this.... the banks are all over it and on top of it. What did you think? They own 20% of our tokens.
You couldn't wish for better partners than 2 or 3 major European banks.... (heavily invol

ITUP

TRAPPER JIM 37 minutes ago

One of my work buddies told me the same thing. He said you know Jim. Most people don't put anywhere close to 10% in their 401Ks. I said I know I know. But I've been working hard on just hammering that thing for my retirement.

sab63090 38 minutes ago

George: surprised you didn't get a thumbs up from more than me!

AVXL

Jack Torrance 44 minutes ago

Like clockwork from these turds. They already tried this once. No one pays attention to these frivolous lawsuits.

IONQ

mugs57 47 minutes ago

1st have accounts at fidelity and etrade and was able to buy in two transactions yesterday at fidelity 10,000 and 4000. i did not try etrade (wish i would have)
Copilot-Yesterday a stock symbol NWBO was restricted from buying at a number of brokerage firms can you confirm and state why and

NWBO

Investor Will 49 minutes ago

Your analysis makes sense JOE (sorry about that).

sab63090 52 minutes ago

Yes, Kund....things will be much more difficult than what most have been expecting!

Remember:

Cramer (CNBC) has always said: "there's always a bull market somewhere"......hopefully that the case for Avanex.

AVXL

LVerstee 53 minutes ago

Claiming banks want this stablecoin doesn’t make it a reality. Until there’s regulatory approval, market adoption, and real trading volume, this remains speculation. If liquidity is real, why isn’t the stablecoin freely tradable today? And why do the tokens show no value on Polyscan (exchange listin

ITUP

Omar8 54 minutes ago

Alwaysred,

https://www.cmegroup.com/markets/metals/precious/silver.volume.html

Pretty big delivery at this level, what is that 50 million ounces ?

SLV

sab63090 57 minutes ago

Yes, the presumed leader which (has been) Nvidia....with the best "fundamentals" based on a lower p/e, strong growth prospects, etc.....

I learned long ago that when the strongest leaders in one calendar year end up with the most praise, they normally don't do as well in the new calen

AVXL

capgain 59 minutes ago

That it was!

sab63090 1 hour ago

Thanks, Citrati and good luck with your recovery, too!

My surgeries were no problem and my wife's left eye surgery went well. This second one caught us off guard and she is very fond of crossword puzzles and likes to read, so this has been an additional problem for her.

AVXL

carvajal 1 hour ago

May 24' , not even a year has passed.

HMBL

Trending Now

Toplists

Market Data

News

Trading Tools

Markets

Discover

Hot Features

Follow Feed

Options Flow

Monitor

Medicenna Therapeutics Corp (MDNA) Share Price

Medicenna Therapeutics Corp (MDNA)

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Key stats and details

About Medicenna Therapeutics Corp

Ask ADVFN Intelligence (AI)

MDNA Latest News

Medicenna Reports MDNA11’s Compelling Anti-Cancer Activity is Associated with Significant Expansion of ‘Stem-Like’ Cancer Fighting Immune Cells at the Inaugural AACR-Immuno-Oncology Conference and Provides ABILITY-1 Study Update

Medicenna Reports Third Quarter Fiscal 2025 Financial and Operational Results and Provides Anticipated Milestones

Medicenna Therapeutics to Participate in Two Healthcare Investor Conferences in February 2025

Medicenna Presents Preclinical Data on MDNA11 as First Step to Shrink Tumors Before Surgery and Prevent Metastasis at the 2024 San Antonio Breast Cancer Symposium (SABCS)

Medicenna Provides Clinical Update and Announces First Complete Responder in MDNA11 and KEYTRUDA® (pembrolizumab) Combination Dose Escalation Arm of the ABILITY-1 Study

Updated MDNA11 Monotherapy and Combination Clinical Data from the Ongoing Phase 1/2 ABILITY-1 Study to be Presented at the 2024 Immunotherapy Bridge Conference

Medicenna Presents Preclinical Data on MDNA11 and Bizaxofusp at the 2024 Annual Meeting of the Society for Neuro-Oncology (SNO)

Medicenna Reports Second Quarter Fiscal 2025 Financial Results and Corporate Update

Medicenna Announces Upcoming Presentations at the 29th Annual Meeting of the Society for Neuro-Oncology (SNO) and the 2024 San Antonio Breast Cancer Symposium (SABCS)

Medicenna Announces Positive Single-Agent Activity of MDNA11 from Dose Expansion Cohort and Encouraging Safety Profile in Combination with KEYTRUDA® (pembrolizumab) at the 39th Annual Meeting of SITC

Medicenna Reports MDNA11’s Compelling Anti-Cancer Activity is Associated with Significant Expansion of ‘Stem-Like’ Cancer Fighting Immune Cells at the Inaugural AACR-Immuno-Oncology Conference and Provides ABILITY-1 Study Update

Medicenna Reports Third Quarter Fiscal 2025 Financial and Operational Results and Provides Anticipated Milestones

Medicenna Therapeutics to Participate in Two Healthcare Investor Conferences in February 2025

Medicenna Presents Preclinical Data on MDNA11 as First Step to Shrink Tumors Before Surgery and Prevent Metastasis at the 2024 San Antonio Breast Cancer Symposium (SABCS)

Medicenna Provides Clinical Update and Announces First Complete Responder in MDNA11 and KEYTRUDA® (pembrolizumab) Combination Dose Escalation Arm of the ABILITY-1 Study

Updated MDNA11 Monotherapy and Combination Clinical Data from the Ongoing Phase 1/2 ABILITY-1 Study to be Presented at the 2024 Immunotherapy Bridge Conference

Medicenna Presents Preclinical Data on MDNA11 and Bizaxofusp at the 2024 Annual Meeting of the Society for Neuro-Oncology (SNO)

Medicenna Reports Second Quarter Fiscal 2025 Financial Results and Corporate Update

MDNA - Frequently Asked Questions (FAQ)

Movers

Discussion

Your Recent History

Company

Business

Popular

Get The App

Go Ad-Free